Subtype
Early Stage Breast Carcinoma
CI-CAN-00002563Explore in graph →
57 active trials2 approved drugs
- NCIt
- C94774
Loading cancer entity…
Subtype
CI-CAN-00002563Explore in graph →
Clinical trials
145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER |
| 0 |
| May 15, 2026 |
| clinicaltrials |
Data updated 22 days agoSource updated Jul 8, 2026source: clinicaltrials